Avalo Therapeutics reported financial results for the quarter ended June 30, 2026, reporting a net loss of $36.4 million and cash reserves of $472.2 million sufficient to fund operations into 2029. The company announced plans to initiate a registrational Phase 3 program for abdakibart in hidradenitis suppurativa (HS) in the first half of 2027, following positive Phase 2 LOTUS results. Additionally, Avalo expects to submit an Investigational New Drug application for AVTX-010, a next-generation anti-IL-1β antibody, in the same timeframe. Ron Philip was appointed to the Board of Directors, and the company was added to the Russell 2000 and Russell 3000 indexes. Avalo Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.

Avalo Therapeutics, Inc. appointed Ron Philip to its Board of Directors, effective June 23, 2026. Mr. Philip will serve on the Compensation Committee and the Science, Development and Commercial Advisory Committee until the 2027 Annual Meeting of Stockholders. As part of his appointment, he will receive a non-qualified stock option to purchase 40,200 shares of common stock, vesting in three equal annual installments. Mr. Philip previously held leadership roles at Spark Therapeutics, Orbital Therapeutics, and Pfizer. Avalo Therapeutics, Inc. is a biotechnology company.

Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody. The therapeutic candidate is being developed for the treatment of hidradenitis suppurativa and other inflammatory disorders. The company also released an updated investor presentation on its website. Avalo Therapeutics is a biotechnology company focused on developing therapies for inflammatory diseases.

Avalo Therapeutics, Inc. entered into an exchange agreement on June 11, 2026, to exchange 4,294.675 shares of Series C non-voting convertible preferred stock for an equivalent number of newly created Series C-1 non-voting convertible preferred stock. This exchange allows an investor to increase their beneficial ownership limit from 4.99% to 9.99% of the Company's common stock. Additionally, the Company amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, M.D., CMO Mittie Doyle, and CBO Taylor Boyd to modify severance and change in control benefits. Avalo Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.

Avalo Therapeutics, Inc. held its 2026 annual meeting of stockholders, where stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) and elected seven board nominees. Additionally, stockholders also ratified the following: Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year 2026.